Tuesday, 11 August 2020


Accenture, Google Cloud team up to assist life science companies

29 January 2020 | News

Accenture’s INTIENT platform on Google Cloud will enhance insights and collaboration in the life sciences market

image credit- businesswire.com

image credit- businesswire.com

Accenture and Google Cloud have announced that Google Cloud will be the cloud technology provider for Accenture’s INTIENT™ life sciences industry platform.

The new, multi-year agreement brings Google’s cloud and artificial intelligence capabilities together with Accenture’s life sciences services and platforms and is intended to help life sciences organizations make their data more accessible, secure and valuable.

The INTIENT platform provides life sciences organizations with end-to-end capabilities from discovery and research to clinical development and the delivery of treatments.

Accenture launched INTIENT in May 2019, building on more than seven years of collaboration with over 25 life sciences companies to develop and deploy platform technology solutions.

Google Cloud’s architecture supports open source technology that will enable Accenture to expand the capabilities of INTIENT by allowing partners, independent software vendors, and content providers to rapidly develop and provide additional solutions that extend the value of the platform.

Under the terms of the agreement, Google Cloud will be the cloud technology provider for current and future solutions that are a part of the Accenture INTIENT platform for life sciences. The agreement is an extension of the partnership between Accenture and Google built over the last eight years. A key milestone in the relationship was the July 2018 launch of the Accenture Google Cloud Business Group, which helps companies use Google Cloud technology to deliver superior customer experiences and accelerate their digital transformation journeys.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls